Press Releases

Oct 19, 2018

FDA approves asthma indication for Dupixent® (dupilumab)

-- Only biologic approved for both moderate and severe asthma patients with eosinophilic phenotype
Oct 16, 2018

Dupixent® (dupilumab) showed positive topline results in two Phase 3 trials of patients with chronic rhinosinusitis with nasal polyps

- Dupixent significantly reduced nasal polyp size, nasal congestion severity, and need for systemic corticosteroids and/or surgery
Sep 28, 2018

FDA approves Libtayo® (cemiplimab-rwlc) as first and only treatment for advanced cutaneous squamous cell carcinoma

* Libtayo is the third anti-PD-1 approved in the U.S.
Sep 12, 2018

FDA to review supplemental Biologics License Application for Praluent® (alirocumab) Injection as potential treatment to reduce major adverse cardiovascular events

* FDA also recently approved Praluent label update for some patients currently requiring LDL apheresis therapy
Sep 4, 2018

Sanofi reaches civil settlement with US SEC

Show per page

Print
Email page
RSS